Welcome!

News Feed Item

IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2017

MONTREAL, QUEBEC -- (Marketwired) -- 06/19/17 -- IBEX Technologies Inc. ("IBEX" or the "Company") (TSX VENTURE:IBT) today reported its financial results for the nine months ended April 30, 2017.

"As expected, sales and net earnings for the 3rd Quarter were up significantly vs. year ago but down vs. the exceptional prior quarter", said Paul Baehr, IBEX President & CEO. "This traces to the highly variable nature of our sales pattern. We are pleased to report that our new fermentation facility is coming along well and is expected to be on-stream by the end this calendar year. Looking forward, we expect sales in the 4th Quarter to be higher than the 3rd Quarter, but net earnings may reflect a modest loss as a result of the normal heavier expenses in the 4th Quarter".

Note: All figures are in Canadian dollars unless otherwise stated. The Company's audited consolidated financial statements for the year ended July 31, 2016 and the accompanying notes and the related management's discussion and analysis can be found on the Company's website at www.ibex.ca or under the Company's profile on SEDAR at www.sedar.com.

THIRD QUARTER FISCAL 2017 FINANCIAL RESULTS

Sales for the quarter ended April 30, 2017 ($1,115,318) were up 60% compared to a very down quarter in the same period of the prior year ($696,200). The sales increase traces mainly to the introduction of a new product by one of our customers which contains an IBEX enzyme (for which we did not benefit in the year-ago period).

Net earnings of $1,450 increased by $464,010 compared to a net loss of $462,560 in the year ago period. The favourable change in earnings traced mainly to the sales increase.

Cash and cash equivalents decreased 4% ($112,645) vs. the previous quarter as a result of the continuing investment in our new fermentation facility ($335,000 in Q3).

FINANCIAL RESULTS FOR THE NINE MONTHS ENDED APRIL 30, 2017

Sales for the nine months ended April 30, 2017 ($3,868,133) are up 19% as compared to the same period of the prior year ($3,251,891). The sales increase traces mainly to the introduction of a new product mentioned above.

Net earnings ($623,024) are up by $528,048 as compared to the same period a year ago ($94,976). This positive variation in earnings can be mainly traced to the increase in sales.

Year-to-date cash and cash equivalents ($3,001,410) are up 4% vs. the end of Fiscal 2016, despite the investment in our new fermentation facility ($461,000), the expansion of our purification capability ($124,000), investments in IT upgrades ($55,000) and routine upgrades to lab equipment ($38,000).

Financial Summary for the nine months ended                                 
----------------------------------------------------------------------------
                                                   April 30,       April 30,
                                                        2017            2016
                                            --------------------------------
Revenues                                       $   3,868,133   $   3,251,891
Earnings before interest, tax, depreciation                                 
 & amortization                                $     860,251   $     386,253
Depreciation                                   $     208,469   $     256,570
Net earnings                                   $     623,024   $      94,976
Earnings per share                             $        0.02   $        0.00

Cash and cash equivalents increased by $101,788 during the nine months ended April 30, 2017 as compared to the year ended July 31, 2016. Net working capital increased by $147,995 during the nine months ended April 30, 2017 as compared to the year ended July 31, 2016.

Balance Sheet Summary as at                                                 
----------------------------------------------------------------------------
                                                   April 30,        July 31,
                                                        2017            2016
                                            --------------------------------
Cash and cash equivalents                      $   3,001,410   $   2,899,622
Net working capital                            $   3,664,184   $   3,516,189
Outstanding shares at report date (common                                   
 shares)                                          24,703,244      24,703,244

LOOKING FORWARD

We expect that the construction of our fermentation facility is on track to be finished in July 2017 (the fourth quarter of this fiscal year) and will be commissioned by the end of this calendar year. The total cost of the facility is unchanged at $600,000 of which $461,000 has already been disbursed. The balance of our investment is expected to be disbursed within the current fiscal year.

The expansion of our purification capability will also be completed by the end of this fiscal year (budgeted at $140,000 of which $124,000 has already been disbursed).

We expect sales in the 4th Quarter to be higher than the current quarter, but net earnings may reflect a modest loss as a result of the normal heavier expenses in the 4th Quarter.

Overall, we expect to end the 2017 Fiscal Year with a cash position similar to 2016, despite the increase in net earnings, tracing to the absorbance of the construction costs of our new fermentation facility.

Management believes that the Company has sufficient funds to meet its obligations and planned expenditures for the ensuing twelve months as they fall due. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period.

ABOUT IBEX

IBEX manufactures and markets proteins for biomedical use through its wholly owned subsidiaries IBEX Pharmaceuticals Inc. (Montreal, QC) and Bio-Research Products, Inc. (North Liberty, IA). IBEX Pharmaceuticals also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research.

For more information, please visit the Company's website at www.ibex.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbor Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, as they are based on the current assessment or expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements, except if required by applicable laws.

In addition to the risk factors identified above, IBEX is, and has been in the past, heavily reliant on three products and five customers, the loss of any of which could have a material effect on its profitability.

Contacts:
Paul Baehr
President & CEO
IBEX Technologies Inc.
514-344-4004 x 143

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
"Digital transformation - what we knew about it in the past has been redefined. Automation is going to play such a huge role in that because the culture, the technology, and the business operations are being shifted now," stated Brian Boeggeman, VP of Alliances & Partnerships at Ayehu, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"WineSOFT is a software company making proxy server software, which is widely used in the telecommunication industry or the content delivery networks or e-commerce," explained Jonathan Ahn, COO of WineSOFT, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
Sanjeev Sharma Joins June 5-7, 2018 @DevOpsSummit at @Cloud Expo New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...